WO2023105479A1 - Use of amivantamab to treat colorectal cancer - Google Patents

Use of amivantamab to treat colorectal cancer Download PDF

Info

Publication number
WO2023105479A1
WO2023105479A1 PCT/IB2022/061991 IB2022061991W WO2023105479A1 WO 2023105479 A1 WO2023105479 A1 WO 2023105479A1 IB 2022061991 W IB2022061991 W IB 2022061991W WO 2023105479 A1 WO2023105479 A1 WO 2023105479A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
seq
subject
administered
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2022/061991
Other languages
English (en)
French (fr)
Inventor
Roland Knoblauch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Priority to AU2022407875A priority Critical patent/AU2022407875A1/en
Priority to MX2024007066A priority patent/MX2024007066A/es
Priority to EP22826446.1A priority patent/EP4444426A1/en
Priority to KR1020247022472A priority patent/KR20240112963A/ko
Priority to JP2024534144A priority patent/JP2025500784A/ja
Priority to CN202280081380.9A priority patent/CN118414167A/zh
Priority to IL313410A priority patent/IL313410A/en
Priority to CA3241933A priority patent/CA3241933A1/en
Publication of WO2023105479A1 publication Critical patent/WO2023105479A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

  • sequence listing of the present application is submitted electronically via The United States Patent and Trademark Center Patent Center as an XML formatted sequence listing with a file name “JBI6688WOPCTlSEQLIST.xml”, creation date of December 2, 2022, and a size of 20 kilobytes (KB).
  • This sequence listing submitted is part of the specification and is herein incorporated by reference in its entirety.
  • the present invention relates to methods of treating colorectal cancer (CRC), such as metastatic colorectal cancer (mCRC), in a subject in need thereof, comprising administering a therapeutically effective amount of an antibody (e.g., a bispecific antibody) to the subject, wherein the antibody specifically binds epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-Met).
  • CRC colorectal cancer
  • mCRC metastatic colorectal cancer
  • an antibody e.g., a bispecific antibody
  • EGFR epidermal growth factor receptor
  • c-Met hepatocyte growth factor receptor
  • CRC Colorectal cancer
  • CRC colorectal cancer
  • mCRC metastatic CRC
  • the disclosure generally relates to methods that are useful for treating CRC (e.g., metastatic colorectal cancer (mCRC)).
  • CRC metastatic colorectal cancer
  • the disclosure provides a method of treating CRC in a subject in need thereof, comprising administering a therapeutically effective amount of an anti- epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody to the subject.
  • EGFR epidermal growth factor receptor
  • c-Met hepatocyte growth factor receptor
  • the antibody is a bispecific antibody.
  • the antibody (e.g., bispecific antibody) comprises: a) a first domain that specifically binds EGFR, comprising heavy chain complementarity determining region 1 (HCDR1), HCDR2, HCDR3, light chain complementarity determining region 1 (LCDR1), LCDR2 and LCDR3 amino acid sequences of SEQ ID NOs: l, 2, 3, 4, 5 and 6, respectively; and b) a second domain that specifically binds c-Met, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 amino acid sequences of SEQ ID NOs:7, 8, 9, 10, 11 and 12, respectively.
  • the first domain comprises a heavy chain variable region (VH) of SEQ ID NO: 13 and a light chain variable region (VL) of SEQ ID NO: 14, and the second domain comprises a VH of SEQ ID NO: 15 and a VL of SEQ ID NO: 16.
  • the antibody (e.g., bispecific antibody) comprises a first heavy chain (HC1) of SEQ ID NO: 17, a first light chain (LC1) of SEQ ID NO: 18, a second heavy chain (HC2) of SEQ ID NO: 19 and a second light chain (LC2) of SEQ ID NO:20.
  • HC1 first heavy chain
  • LC1 first light chain
  • HC2 second heavy chain
  • LC2 second light chain
  • the antibody e.g., bispecific antibody
  • the antibody is of the IgGl isotype.
  • the antibody e.g., bispecific antibody
  • the antibody e.g., bispecific antibody
  • the antibody e.g., bispecific antibody
  • the antibody is administered at a dose of about 700 mg to about 1,400 mg.
  • the antibody e.g., bispecific antibody
  • the antibody is administered once a week or once every two weeks.
  • the antibody e.g., bispecific antibody
  • the antibody is administered once weekly for the first 4 weeks and then every 2 weeks.
  • the antibody is administered on a 28-day cycle.
  • the antibody e.g., bispecific antibody
  • the method further comprises administering one or more chemotherapeutic agents to the subject.
  • the one or more chemotherapeutic agents comprise FOLFOX, wherein FOLFOX comprises folinic acid, fluorouracil and oxaliplatin.
  • the one or more chemotherapeutic agents comprise FOLFIRI, wherein FOLFIRI comprises folinic acid, fluorouracil and irinotecan.
  • the CRC is mCRC.
  • the subject has been diagnosed with left-sided mCRC. In other embodiments, the subject has been diagnosed with right-sided mCRC.
  • the subject is anti -EGFR therapy naive. In other embodiments, the subject has received prior anti-EGFR therapy. In certain embodiments, the subject is relapsed or resistant to treatment with one or more prior anti-cancer therapies. In some embodiments, the subject is treatment naive. In some embodiments, the subject has not received oxaliplatin-based chemotherapy in a metastatic setting.
  • the subject is 18 years of age or older. In some embodiments, the subject has been characterized with wild-type KRAS, NRAS and BRAF.
  • the disclosure provides a method of treating mCRC in a subject, comprising administering a therapeutically effective amount of an isolated bispecific anti- EGFR/c-Met antibody to the subject, wherein the bispecific anti-EGFR/c-Met antibody comprises a first domain that specifically binds EGFR and a second domain that specifically binds c-Met, wherein the first domain comprises a HCDR1 of SEQ ID NO: 1, a HCDR2 of SEQ ID NO: 2, a HCDR3 of SEQ ID NO: 3, a LCDR1 of SEQ ID NO: 4, a LCDR2 of SEQ ID NO: 5 and a LCDR3 of SEQ ID NO: 6; and the second domain comprises the HCDR1 of SEQ ID NO: 7, the HCDR2 of SEQ ID NO: 8, the HCDR3 of SEQ ID NO: 9, the LCDR1 of SEQ ID NO: 10, the LCDR2 of SEQ ID NO: 11 and the LCDR3 of SEQ ID NO: 12.
  • the disclosure provides a method of treating mCRC in a subject, comprising administering a therapeutically effective amount of an isolated bispecific anti- EGFR/c-Met antibody to the subject, wherein the bispecific anti-EGFR/c-Met antibody comprises a first domain that specifically binds EGFR and a second domain that specifically binds c-Met, wherein the first domain comprises a VH of SEQ ID NO: 13 and a VL of SEQ ID NO: 14; and the second domain comprises the VH of SEQ ID NO: 15 and the VL of SEQ ID NO: 16.
  • the disclosure provides a method of treating mCRC in a subject, comprising administering a therapeutically effective amount of an isolated bispecific anti- EGFR/c-Met antibody to the subject, wherein the bispecific anti-EGFR/c-Met antibody comprises a HC1 of SEQ ID NO: 17, a LC1 of SEQ ID NO: 18, a HC2 of SEQ ID NO: 19 and a LC2 of SEQ ID NO: 20.
  • the disclosure provides a method of treating mCRC in a subject, comprising administering a therapeutically effective amount of an isolated bispecific anti- EGFR/c-Met antibody to the subject, wherein the bispecific anti-EGFR/c-Met antibody is amivantamab.
  • FIG. 1 shows a study design for Phase lb/2, open-label study of amivantamab in patients with advanced or metastatic colorectal cancer.
  • FIG. 2 shows a schematic of the structure of amivantamab, an EGFR and cMet bispecific antibody.
  • transitional terms “comprising,” “consisting essentially of,” and “consisting of’ are intended to connote their generally accepted meanings in the patent vernacular; that is, (i) “comprising,” which is synonymous with “including,” “containing,” or “characterized by,” is inclusive or open-ended and does not exclude additional, unrecited elements or method steps; (ii) “consisting of’ excludes any element, step, or ingredient not specified in the claim; and (iii) “consisting essentially of’ limits the scope of a claim to the specified materials or steps “and those that do not materially affect the basic and novel characteristic(s)” of the claimed invention.
  • Embodiments described in terms of the phrase “comprising” (or its equivalents) also provide as embodiments those independently described in terms of “consisting of’ and “consisting essentially of.”
  • “About” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. Unless explicitly stated otherwise within the Examples or elsewhere in the Specification in the context of a particular assay, result or embodiment, “about” means within one standard deviation per the practice in the art, or a range of up to 5%, whichever is larger.
  • antibody or “antibodies” is meant in a broad sense and includes immunoglobulin molecules including monoclonal antibodies including murine, human, humanized and chimeric monoclonal antibodies, full-length antibodies, antigen binding fragments, multispecific antibodies, such as bispecific, trispecific, tetraspecific etc., dimeric, tetrameric or multimeric antibodies, single chain antibodies, domain antibodies and any other modified configuration of the immunoglobulin molecule that comprises an antigen binding site of the required specificity.
  • “Specific binding” or “specifically binds” or “specifically binding” or “binds” refer to an antibody binding to an antigen or an epitope within the antigen with greater affinity than for other antigens.
  • the antibody binds to the antigen or the epitope within the antigen with an equilibrium dissociation constant (KD) of about 5xl0' 8 M or less, for example about IxlO' 9 M or less, about IxlO' 10 M or less, about IxlO' 11 M or less, or about IxlO' 12 M or less, typically with the KD that is at least one hundred-fold less than its KD for binding to a non-specific antigen (e.g., BSA, casein).
  • KD equilibrium dissociation constant
  • the dissociation constant may be measured using known protocols.
  • Antibodies that bind to the antigen or the epitope within the antigen may, however, have cross-reactivity to other related antigens, for example to the same antigen from other species (homologs), such as human or monkey, for example Macaca fasciculciris (cynomolgus, cyno) or Pan troglodytes (chimpanzee, chimp). While a monospecific antibody binds one antigen or one epitope, a bispecific antibody binds two distinct antigens or two distinct epitopes.
  • CDR complementarity determining regions
  • CDR CDR
  • HCDR1 CDR1
  • HCDR2 CDR3
  • LCDR1 CDR2
  • LCDR3 CDR3
  • Full-length antibodies are comprised of two heavy chains (HC) and two light chains (LC) inter-connected by disulfide bonds as well as multimers thereof (e.g., IgM).
  • Each heavy chain is comprised of a heavy chain variable region (VH) and a heavy chain constant region (comprised of domains CHI, hinge, CH2 and CH3).
  • Each light chain is comprised of a light chain variable region (VL) and a light chain constant region (CL).
  • the VH and the VL regions may be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with framework regions (FR).
  • CDR complementarity determining regions
  • FR framework regions
  • Each VH and VL is composed of three CDRs and four FR segments, arranged from amino-to-carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4.
  • Antigen binding fragment refers to a portion of an immunoglobulin molecule that binds an antigen.
  • Antigen binding fragments may be synthetic, enzymatically obtainable or genetically engineered polypeptides and include the VH, the VL, the VH and the VL, Fab, F(ab')2, Fd and Fv fragments, domain antibodies (dAb) consisting of one VH domain or one VL domain, shark variable IgNAR domains, camelized VH domains, minimal recognition units consisting of the amino acid residues that mimic the CDRs of an antibody, such as FR3- CDR3-FR4 portions, the HCDR1, the HCDR2 and/or the HCDR3 and the LCDR1, the LCDR2 and/or the LCDR3.
  • VH and VL domains may be linked together via a synthetic linker to form various types of single chain antibody designs where the VH/VL domains may pair intramolecularly, or intermolecularly in those cases when the VH and VL domains are expressed by separate single chain antibody constructs, to form a monovalent antigen binding site, such as single chain Fv (scFv) or diabody; described for example in Int. Patent Publ. Nos. W01998/44001, WO1988/01649, WO1994/13804 and W01992/01047.
  • scFv single chain Fv
  • “Monoclonal antibody” refers to an antibody obtained from a substantially homogenous population of antibody molecules, i.e., the individual antibodies comprising the population are identical except for possible well-known alterations such as removal of C- terminal lysine from the antibody heavy chain or post-translational modifications such as amino acid isomerization or deamidation, methionine oxidation or asparagine or glutamine deamidation.
  • Monoclonal antibodies typically bind one antigenic epitope.
  • a bispecific monoclonal antibody binds two distinct antigenic epitopes.
  • Monoclonal antibodies may have heterogeneous glycosylation within the antibody population.
  • Monoclonal antibody may be monospecific or multispecific such as bispecific, monovalent, bivalent or multivalent.
  • Humanized antibodies refers to antibodies in which the antigen binding sites are derived from non-human species and the variable region frameworks are derived from human immunoglobulin sequences. Humanized antibodies may include intentionally introduced mutations in the framework regions so that the framework may not be an exact copy of expressed human immunoglobulin or germline gene sequences.
  • Human antibodies refers to antibodies having heavy and light chain variable regions in which both the framework and the antigen binding site are derived from sequences of human origin. If the antibody contains a constant region or a portion of the constant region, the constant region is also derived from sequences of human origin. Antibodies in which antigen binding sites are derived from a non-human species are not included in the definition of “human antibody.”
  • a human antibody comprises heavy or light chain variable regions that are derived from sequences of human origin if the variable regions of the antibody are obtained from a system that uses human germline immunoglobulin or rearranged immunoglobulin genes.
  • Non-limiting example systems include human immunoglobulin gene libraries displayed on phage, and transgenic non-human animals such as mice or rats carrying human immunoglobulin loci.
  • a human antibody typically contains amino acid differences when compared to the human germline or rearranged immunoglobulin sequences due to, for example, naturally occurring somatic mutations, intentional substitutions in the framework or antigen binding site, and substitutions introduced during cloning or VDJ recombination in non-human animals.
  • a human antibody is at least 80% identical in amino acid sequence to an amino acid sequence encoded by a human germline or rearranged immunoglobulin gene. For example, about: 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical.
  • a human antibody may contain consensus framework sequences derived from human framework sequence analyses (see, e.g., Knappik et al., J. Mol. Biol.
  • Bispecific refers to an antibody that specifically binds two distinct antigens or two distinct epitopes within the same antigen.
  • the bispecific antibody may have crossreactivity to other related antigens, for example to the same antigen from other species (homologs), such as human or monkey, for example Macaca cynomolgus (cynomolgus, cyno) or Pan troglodytes, or may bind an epitope that is shared between two or more distinct antigens.
  • Bispecific anti-EGFR/c-Met antibody or “bispecific EGFR/c-Met antibody” refers to a bispecific antibody having a first domain that specifically binds EGFR and a second domain that specifically binds c-Met.
  • the domains specifically binding EGFR and c- Met are typically VH/VL pairs, and the bispecific anti-EGFR/c-Met antibody is monovalent in terms of binding to EGFR and c-Met.
  • isolated refers to a homogenous population of molecules (such as synthetic polynucleotides, polypeptides vectors or viruses) which have been substantially separated and/or purified away from other components of the system the molecules are produced in, such as a recombinant cell, as well as a protein that has been subjected to at least one purification or isolation step.
  • molecules such as synthetic polynucleotides, polypeptides vectors or viruses
  • isolated refers to a molecule that is substantially free of other cellular material and/or chemicals and encompasses molecules that are isolated to a higher purity, such as to 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% purity.
  • Immunoglobulins may be assigned to five major classes, IgA, IgD, IgE, IgG and IgM, depending on the heavy chain constant domain amino acid sequence.
  • IgA and IgG are further sub-classified as the isotypes IgAl, IgA2, IgGl, IgG2, IgG3 and IgG4.
  • Antibody light chains of any vertebrate species may be assigned to one of two clearly distinct types, namely kappa (K) and lambda (X), based on the amino acid sequences of their constant domains.
  • K kappa
  • X lambda
  • Normal fucose or ‘normal fucose content” as used herein refers to antibodies with fucose content of about over 50%, typically about over 80% or over 85%.
  • Recombinant refers to DNA, antibodies and other proteins that are prepared, expressed, created or isolated by recombinant means when segments from different sources are joined to produce recombinant DNA, antibodies or proteins.
  • Carrier refers to a diluent, adjuvant, excipient, or vehicle with which the antibody of the invention is administered.
  • vehicles may be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
  • 0.4% saline and 0.3% glycine may be used to formulate the bispecific anti-EGFR/c-Met antibody.
  • These solutions are sterile and generally free of particulate matter. They may be sterilized by conventional, well- known sterilization techniques (e.g. , filtration).
  • the carrier may comprise sterile water and other excipients may be added to increase solubility or preservation.
  • Injectable suspensions or solutions may also be prepared utilizing aqueous carriers along with appropriate additives.
  • Suitable vehicles and formulations, inclusive of other human proteins, e.g., human serum albumin, are described, for example, in e.g., Remington: The Science and Practice of Pharmacy, 21 st Edition, Troy, D.B. ed., Lipincott Williams and Wilkins, Philadelphia, PA 2006, Part 5, Pharmaceutical Manufacturing pp 691- 1092, See especially pp. 958-989.
  • Dosage refers to the information of the amount of the therapeutic or the drug to be taken by the subject and the frequency of the number of times the therapeutic is to be taken by the subject. “Dose” refers to the amount or quantity of the therapeutic or the drug to be taken each time.
  • “Therapeutically effective amount” refers to an amount effective, at doses and for periods of time necessary, to achieve a desired therapeutic result.
  • a therapeutically effective amount may vary depending on factors such as the disease state, age, sex, and weight of the individual, and the ability of a therapeutic or a combination of therapeutics to elicit a desired response in the individual. Exemplary indicators of an effective therapeutic or combination of therapeutics that include, for example, improved well-being of the patient.
  • ‘Fixed combination” refers to a single pharmaceutical composition comprising two or more compounds.
  • Non-fixed combination refers to separate pharmaceutical compositions, wherein each comprises one or more compounds.
  • the one or more compounds or unit dosage forms can be administered as separate entities either simultaneously, concurrently or sequentially with no specific intervening time limits, wherein such administration provides effective levels of the two compounds in the body of the subject.
  • PD-(L)1 axis inhibitor refers to a molecule that inhibits PD-1 downstream signaling.
  • PD-(L)1 axis inhibitor may be a molecule that binds PD-1, PD-L1 or PD-L2.
  • “Antagonist” or “inhibitor” refers to a molecule that, when bound to a cellular protein, suppresses at least one reaction or activity that is induced by a natural ligand of the protein.
  • a molecule is an antagonist when the at least one reaction or activity is suppressed by at least about 20%, 30%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% more than the at least one reaction or activity suppressed in the absence of the antagonist (e.g. , negative control), or when the suppression is statistically significant when compared to the suppression in the absence of the antagonist.
  • ‘Treat”, “treating” or “treatment” of a disease or disorder such as cancer refers to accomplishing one or more of the following: reducing the severity and/or duration of the disorder, inhibiting worsening of symptoms characteristic of the disorder being treated, limiting or preventing recurrence of the disorder in subjects that have previously had the disorder, or limiting or preventing recurrence of symptoms in subjects that were previously symptomatic for the disorder.
  • ‘Prevent”, “preventing”, “prevention”, or “prophylaxis” of a disease or disorder means preventing that a disorder occurs in subject.
  • “Responsive”, “responsiveness” or “likely to respond” refers to any kind of improvement or positive response, such as alleviation or amelioration of one or more symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable.
  • Subject includes any human or nonhuman animal.
  • Nonhuman animal includes all vertebrates, e.g., mammals and non-mammals, such as nonhuman primates, sheep, dogs, cats, horses, cows, chickens, amphibians, reptiles, etc.
  • the terms “subject” and “patient” are used interchangeably herein.
  • Cancer refers to an abnormal growth of cells which tend to proliferate in an uncontrolled way and, in some cases, to metastasize (spread) to other areas of a patient’s body.
  • EGFR or c-Met expressing cancer refers to cancer that has detectable expression of EGFR or c-Met or has EGFR or c-Met mutation or amplification.
  • EGFR or c- Met expression, amplification and mutation status can be detected using know methods, such as sequencing, next generation sequencing, fluorescent in situ hybridization, immunohistochemistry, flow cytometry or western blotting.
  • Epidermal growth factor receptor or “EGFR” refers to the human EGFR (also known as HER1 or ErbBl (Ullrich et al., Nature 309:418-425, 1984) having the amino acid sequence shown in GenBank accession number NP_005219, as well as naturally-occurring variants thereof.
  • Hepatocyte growth factor receptor or “c-Met” as used herein refers to the human c-Met having the amino acid sequence shown in GenBank Accession No: NP_001120972 and natural variants thereof.
  • Newly diagnosed refers to a subject who has been diagnosed with EGFR or c- Met expressing cancer but has not yet received treatment for CRC (e.g. , mCRC).
  • CRC e.g. , mCRC
  • Refractory refers to a disease that does not respond to a treatment.
  • a refractory disease can be resistant to a treatment before or at the beginning of the treatment, or a refractory disease can become resistant during a treatment.
  • Relapsed refers to the return of a disease or the signs and symptoms of a disease after a period of improvement after prior treatment with a therapeutic.
  • Diagnosing refers to methods to determine if a subject is suffering from a given disease or condition or may develop a given disease or condition in the future or is likely to respond to treatment for a prior diagnosed disease or condition, i.e., stratifying a patient population on likelihood to respond to treatment. Diagnosis is typically performed by a physician based on the general guidelines for the disease to be diagnosed or other criteria that indicate a subject is likely to respond to a particular treatment.
  • Biological sample refers to a collection of similar fluids, cells, or tissues isolated from a subject, as well as fluids, cells, or tissues present within a subject.
  • Exemplary samples are biological fluids such as blood, serum and serosal fluids, plasma, lymph, urine, saliva, cystic fluid, tear drops, feces, sputum, mucosal secretions of the secretory tissues and organs, vaginal secretions, ascites fluids, fluids of the pleural, pericardial, peritoneal, abdominal and other body cavities, fluids collected by bronchial lavage, synovial fluid, liquid solutions contacted with a subject or biological source, for example, cell and organ culture medium including cell or organ conditioned medium, lavage fluids and the like, tissue biopsies, tumor tissue biopsies, tumor tissue samples, fine needle aspirations, surgically resected tissue, organ cultures or cell cultures.
  • the disclosure provides a method of treating CRC in a subject in need thereof, comprising administering a therapeutically effective amount of an anti- epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody to the subject.
  • EGFR epidermal growth factor receptor
  • c-Met hepatocyte growth factor receptor
  • the anti-EGFR/c-Met antibody is a bispecific antibody.
  • the antibody is an isolated antibody.
  • the antibody is an isolated bispecific antibody.
  • the antibody (e.g., bispecific antibody) comprises a first domain that specifically binds EGFR and a second domain that specifically binds c-Met.
  • the first domain that specifically binds EGFR comprises: a) heavy chain complementarity determining region 1 (HCDR1), HCDR2, HCDR3 amino acid sequences of SEQ ID NOs: 1, 2 and 3, respectively; and/or b) light chain complementarity determining region 1 (LCDR1), LCDR2 and LCDR3 amino acid sequences of SEQ ID NOs:4, 5 and 6, respectively.
  • HCDR1 heavy chain complementarity determining region 1
  • HCDR2 HCDR3 amino acid sequences of SEQ ID NOs: 1, 2 and 3, respectively
  • LCDR1 light chain complementarity determining region 1
  • LCDR2 and LCDR3 amino acid sequences of SEQ ID NOs:4, 5 and 6, respectively respectively.
  • the first domain that specifically binds EGFR comprises: a) HCDR1, HCDR2, HCDR3 amino acid sequences of SEQ ID NOs: 1, 2 and 3, respectively; and b) LCDR1, LCDR2 and LCDR3 amino acid sequences of SEQ ID NOs:4, 5 and 6, respectively.
  • HCDR1 TYGMH (SEQ ID NO : 1 )
  • HCDR2 VIWDDGSYKYYGDSVKG (SEQ ID NO:2)
  • HCDR3 DGITMVRGVMKDYFDY (SEQ ID NO: 3)
  • HCDR1 RASQDISSALV (SEQ ID NO:4)
  • HCDR2 DASSLES (SEQ ID N0:5)
  • HCDR3 QQFNSYPLT (SEQ ID N0:6)
  • the first domain comprises a heavy chain variable region (VH) amino acid sequence that is at least 90% identical to SEQ ID NO: 13, e.g., about: 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% identical to SEQ ID NO: 13.
  • VH heavy chain variable region
  • the sequence identity is about: 90-99.9%, 90-99.8%, 92-99.8%, 92-99.6%, 94-99.6%, 94-99.5%, 95- 99.5%, 95-99.4%, 96-99.4%, 96-99.2%, 97-99.2% or 97-99%.
  • the first domain comprises a VH of SEQ ID NO: 13.
  • the first domain comprises a light chain variable region (VL) amino acid sequence that is at least 90% identical to SEQ ID NO: 14, e.g., about: 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% identical to SEQ ID NO: 14.
  • VL light chain variable region
  • the sequence identity is about: 90-99.9%, 90-99.8%, 92-99.8%, 92-99.6%, 94-99.6%, 94-99.5%, 95- 99.5%, 95-99.4%, 96-99.4%, 96-99.2%, 97-99.2% or 97-99%.
  • the first domain comprises a VL of SEQ ID NO: 14.
  • the term “identical” or “has sequence identity,” refers to the extent to which two amino acid sequences have the same residues at the same positions when the sequences are aligned to achieve a maximal level of identity, expressed as a percentage.
  • sequence alignment and comparison typically one sequence is designated as a reference sequence, to which a test sequences are compared.
  • sequence identity between reference and test sequences is expressed as the percentage of positions across the entire length of the reference sequence where the reference and test sequences share the same amino acid upon alignment of the reference and test sequences to achieve a maximal level of identity.
  • two sequences are considered to have 70% sequence identity when, upon alignment to achieve a maximal level of identity, the test sequence has the same amino acid residue at 70% of the same positions over the entire length of the reference sequence.
  • the first domain comprises: a) a VH amino acid sequence that is at least 90% identical to SEQ ID NO: 13; and/or b) a VL amino acid sequence that is at least 90% identical to SEQ ID NO: 14.
  • the first domain comprises: a) a VH amino acid sequence that is at least 90% identical to SEQ ID NO: 13; and b) a VL amino acid sequence that is at least 90% identical to SEQ ID NO: 14.
  • the first domain comprises: a) a VH of SEQ ID NO: 13; and/or b) a VL of SEQ ID NO: 14.
  • the first domain comprises: a) a VH of SEQ ID NO: 13; and b) a VL of SEQ ID NO: 14.
  • VH QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLE WVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGI TMVRGVMKDYFDYWGQGTLVTVSS (SEQ ID NO: 13)
  • VL AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIY DASSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK (SEQ ID NO: 14)
  • the first domain comprises a first heavy chain (HC1) amino acid sequence that is at least 80% identical to SEQ ID NO: 17, e.g., about: 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% identical to SEQ ID NO: 17.
  • HC1 first heavy chain amino acid sequence that is at least 80% identical to SEQ ID NO: 17, e.g., about: 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%,
  • the sequence identity is about: 80-99.9%, 80- 99.8%, 85-99.8%, 85-99.6%, 90-99.6%, 90-99.5%, 95-99.5%, 95-99.4%, 96-99.4%, 96- 99.2%, 97-99.2% or 97-99%.
  • the first domain comprises a HC1 amino acid sequence of SEQ ID NO: 17.
  • the first domain comprises a first light chain (LC1) amino acid sequence that is at least 80% identical to SEQ ID NO: 18, e.g., about: 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% identical to SEQ ID NO: 18.
  • LC1 first light chain
  • the sequence identity is about: 80-99.9%, 80-99.8%, 85- 99.8%, 85-99.6%, 90-99.6%, 90-99.5%, 95-99.5%, 95-99.4%, 96-99.4%, 96-99.2%, 97- 99.2% or 97-99%.
  • the first domain comprises a LC1 amino acid sequence of SEQ ID NO: 18.
  • the first domain comprises: a) a HC1 amino acid sequence that is at least 80% identical to SEQ ID NO: 17; and/or b) a LC1 amino acid sequence that is at least 80% identical to SEQ ID NO: 18.
  • the first domain comprises: a) a HC1 amino acid sequence that is at least 80% identical to SEQ ID NO: 17; and b) a LC1 amino acid sequence that is at least 80% identical to SEQ ID NO: 18.
  • the first domain comprises: a) a HC1 of SEQ ID NO: 17; and/or b) a LC1 of SEQ ID NO: 18.
  • the first domain comprises: a) a HC1 of SEQ ID NO: 17; and b) a LC1 of SEQ ID NO: 18.
  • HC 1 QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGL
  • LC1 AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLI YDASSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVT EQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 18) c-Met binding arm
  • the second domain that specifically binds c-Met comprises: a) HCDR1, HCDR2, HCDR3 amino acid sequences of SEQ ID NOs:7, 8 and 9, respectively; and/or b) LCDR1, LCDR2 and LCDR3 amino acid sequences of SEQ ID NOs: 10, 11 and 12, respectively.
  • the second domain that specifically binds c-Met comprises: a) HCDR1, HCDR2, HCDR3 amino acid sequences of SEQ ID NOs:7, 8 and 9, respectively; and b) LCDR1, LCDR2 and LCDR3 amino acid sequences of SEQ ID NOs: 10, 11 and 12, respectively.
  • HCDR1 SYGIS (SEQ ID NO : 7)
  • HCDR2 WISAYNGYTNYAQKLQG (SEQ ID NO: 8)
  • HCDR3 DLRGTNYFDY (SEQ ID NO:9)
  • HCDR1 RASQGISNWLA (SEQ ID NO: 10)
  • HCDR2 AASSLLS (SEQ ID NO: 11)
  • HCDR3 QQANSFPIT (SEQ ID NO: 12)
  • the second domain comprises a VH amino acid sequence that is at least 90% identical to SEQ ID NO: 15, e.g, about: 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% identical to SEQ ID NO: 15.
  • the sequence identity is about: 90- 99.9%, 90-99.8%, 92-99.8%, 92-99.6%, 94-99.6%, 94-99.5%, 95-99.5%, 95-99.4%, 96- 99.4%, 96-99.2%, 97-99.2% or 97-99%.
  • the second domain comprises a VH of SEQ ID NO: 15
  • the second domain comprises a VL amino acid sequence that is at least 90% identical to SEQ ID NO: 16, e.g., about: 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% identical to SEQ ID NO: 16.
  • the sequence identity is about: 90- 99.9%, 90-99.8%, 92-99.8%, 92-99.6%, 94-99.6%, 94-99.5%, 95-99.5%, 95-99.4%, 96- 99.4%, 96-99.2%, 97-99.2% or 97-99%.
  • the second domain comprises a VL of SEQ ID NO: 16.
  • the second domain comprises: a) a VH amino acid sequence that is at least 90% identical to SEQ ID NO: 15; and/or b) a VL amino acid sequence that is at least 90% identical to SEQ ID NO: 16.
  • the second domain comprises: a) a VH amino acid sequence that is at least 90% identical to SEQ ID NO: 15; and b) a VL amino acid sequence that is at least 90% identical to SEQ ID NO: 16. [0108] In some embodiments, the second domain comprises: a) a VH of SEQ ID NO : 15 ; and/or b) a VL of SEQ ID NO: 16.
  • the second domain comprises: a) a VH of SEQ ID NO: 15; and b) a VL of SEQ ID NO: 16.
  • VH QVQLVQSGAEVKKPGASVKVSCETSGYTFTSYGISWVRQAPGHGLE WMGWISAYNGYTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDL RGTNYFDYWGQGTLVTVSS (SEQ ID NO: 15)
  • VL DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWFQHKPGKAPKLLI YAASSLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPITFGQGTRLEIK (SEQ ID NO: 16)
  • the second domain comprises a second heavy chain (HC2) amino acid sequence that is at least 80% identical to SEQ ID NO: 19, e.g., about: 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% identical to SEQ ID NO: 19.
  • HC2 second heavy chain amino acid sequence that is at least 80% identical to SEQ ID NO: 19, e.g., about: 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%,
  • the sequence identity is about: 80-99.9%, 80- 99.8%, 85-99.8%, 85-99.6%, 90-99.6%, 90-99.5%, 95-99.5%, 95-99.4%, 96-99.4%, 96- 99.2%, 97-99.2% or 97-99%.
  • the second domain comprises a HC2 amino acid sequence of SEQ ID NO: 19.
  • the second domain comprises a second light chain (LC2) amino acid sequence that is at least 80% identical to SEQ ID NO:20, e.g., about: 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% identical to SEQ ID NO:20.
  • LC2 second light chain amino acid sequence that is at least 80% identical to SEQ ID NO:20, e.g., about: 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99
  • the sequence identity is about: 80-99.9%, 80- 99.8%, 85-99.8%, 85-99.6%, 90-99.6%, 90-99.5%, 95-99.5%, 95-99.4%, 96-99.4%, 96- 99.2%, 97-99.2% or 97-99%.
  • the second domain comprises a LC2 amino acid sequence of SEQ ID NO:20.
  • the second domain comprises: a) a HC2 amino acid sequence that is at least 80% identical to SEQ ID NO: 19; and/or b) a LC2 amino acid sequence that is at least 80% identical to SEQ ID NO:20.
  • the second domain comprises: a) a HC2 amino acid sequence that is at least 80% identical to SEQ ID NO: 19; and b) a LC2 amino acid sequence that is at least 80% identical to SEQ ID NO:20.
  • the second domain comprises: a) a HC2 of SEQ ID NO: 19; and/or b) a LC2 of SEQ ID NO: 20.
  • the second domain comprises: a) a HC2 of SEQ ID NO: 19; and b) a LC2 of SEQ ID NO: 20.
  • HC2 QVQLVQSGAEVKKPGASVKVSCETSGYTFTSYGISWVRQAPGHGLE WMGWISAYNGYTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDL RGTNYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVD KRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS NKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRW
  • LC2 DIQMTQSPSSVSASVGDRVT1TCRASQGISNWLAWFQHKPGKAPKLL IYAASSLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPITFGQGTRLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVT EQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 20)
  • the antibody (e.g., bispecific antibody) comprises: a) a first domain that specifically binds EGFR, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 amino acid sequences of SEQ ID NOs: 1, 2, 3, 4, 5 and 6, respectively; and/or b) a second domain that specifically binds c-Met, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 amino acid sequences of SEQ ID NOs:7, 8, 9, 10, 11 and 12, respectively.
  • the antibody (e.g., bispecific antibody) comprises: a) a first domain that specifically binds EGFR, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 amino acid sequences of SEQ ID NOs: 1, 2, 3, 4, 5 and 6, respectively; and b) a second domain that specifically binds c-Met, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 amino acid sequences of SEQ ID NOs:7, 8, 9, 10, 11 and 12, respectively.
  • the antibody (e.g., bispecific antibody) comprises: a) a first domain comprising a VH amino acid sequence that is at least 90% identical to SEQ ID NO: 13; b) a first domain comprising a VL amino acid sequence that is at least 90% identical to SEQ ID NO: 14; c) a second domain comprising a VH amino acid sequence that is at least 90% identical to SEQ ID NO: 15; and/or d) a second domain comprising a VL amino acid sequence that is at least 90% identical to SEQ ID NO: 16.
  • the antibody (e.g., bispecific antibody) comprises: a) a first domain comprising a VH amino acid sequence that is at least 90% identical to SEQ ID NO: 13; b) a first domain comprising a VL amino acid sequence that is at least 90% identical to SEQ ID NO: 14; c) a second domain comprising a VH amino acid sequence that is at least 90% identical to SEQ ID NO: 15; and d) a second domain comprising a VL amino acid sequence that is at least 90% identical to SEQ ID NO: 16.
  • the antibody (e.g., bispecific antibody) comprises: a) a first domain comprising a VH of SEQ ID NO: 13; b) a first domain comprising a VL of SEQ ID NO: 14; c) a second domain comprising a VH of SEQ ID NO: 15; and/or d) a second domain comprising a VL of SEQ ID NO: 16.
  • the antibody (e.g., bispecific antibody) comprises: a) a first domain comprising a VH of SEQ ID NO: 13; b) a first domain comprising a VL of SEQ ID NO: 14; c) a second domain comprising a VH of SEQ ID NO: 15; and d) a second domain comprising a VL of SEQ ID NO: 16.
  • the antibody (e.g., bispecific antibody) comprises: a) a HC1 amino acid sequence that is at least 80% identical to SEQ ID NO: 17; b) a LC 1 amino acid sequence that is at least 80% identical to SEQ ID NO: 18; c) a HC2 amino acid sequence that is at least 80% identical to SEQ ID NO: 19; and/or d) a LC2 amino acid sequence that is at least 80% identical to SEQ ID NO:20.
  • the antibody (e.g., bispecific antibody) comprises: a) a HC1 amino acid sequence that is at least 80% identical to SEQ ID NO: 17; b) a LC 1 amino acid sequence that is at least 80% identical to SEQ ID NO: 18; c) a HC2 amino acid sequence that is at least 80% identical to SEQ ID NO: 19; and d) a LC2 amino acid sequence that is at least 80% identical to SEQ ID NO:20.
  • the antibody (e.g., bispecific antibody) comprises: a) a HC1 of SEQ ID NO: 17; b) a LC1 of SEQ ID NO: 18; c) a HC2 of SEQ ID NO: 19; and/or d) a LC2 of SEQ ID NO: 20.
  • the antibody (e.g., bispecific antibody) comprises: a) a HC1 of SEQ ID NO: 17; b) a LC1 of SEQ ID NO: 18; c) a HC2 of SEQ ID NO: 19; and d) a LC2 of SEQ ID NO: 20.
  • the antibody e.g., bispecific antibody
  • the antibody is of the IgG isotype.
  • the antibody is of the IgGl isotype.
  • Some variation exists within the IgGl constant domain e.g., well-known allotypes), for example, with variation at positions 214, 356, 358, 422, 431, 435 and/or 436 (residue numbering according to the EU numbering) (see e.g., IMGT Web resources; IMGT Repertoire (IG and TR); Proteins and alleles; allotypes).
  • the bispecific anti-EGFR/c-Met antibody may be of any IgGl allotype, such as Glml7, Glm3, Glml, Glm2, Glm27 or Glm28.
  • the antibody is a human antibody.
  • the antibody is amivantamab.
  • Amivantamab or JNJ- 61186372 (JNJ-372) is an IgGl anti-EGFR/c-Met bispecific antibody described in U.S. Pat. No. 9,593,164.
  • a schematic of the structure of amivantamab is shown in FIG. 2. The disclosure is based, at least in part, on the finding that amivantamab is effective in treating CRC such as mCRC.
  • anti-EGFR/c-Met antibodies may also be used in the methods of the disclosure, for example, by combining publicly available EGFR binding VH/VL domains and c-Met binding VH/VL domains.
  • the antibody comprises a biantennary glycan structure with a fucose content of between about 1% to about 15%.
  • Antibodies with reduced fucose content can be made using different methods reported to lead to the successful expression of relatively high defiicosylated antibodies bearing the biantennary complex-type of Fc oligosaccharides such as control of culture osmolality (Konno et al., Cytotechnology 64(:249-65, 2012), application of a variant CHO line Lecl3 as the host cell line (Shields et al., J Biol Chem 277:26733-26740, 2002), application of a variant CHO line EB66 as the host cell line (Olivier et al., MAbs ;2(4), 2010; Epub ahead of print; PMID:20562582), application of a rat hybridoma cell line YB2/0 as the
  • Anti-EGFR/c-Met antibodies used in the methods of the disclosure may be generated, for example, using Fab arm exchange (or half molecule exchange) between two monospecific bivalent antibodies by introducing substitutions at the heavy chain CH3 interface in each half molecule to favor heterodimer formation of two antibody half molecules having distinct specificity either in vitro in cell-free environment or using coexpression.
  • the Fab arm exchange reaction is the result of a disulfide -bond isomerization reaction and dissociation-association of CH3 domains. The heavy chain disulfide bonds in the hinge regions of the parental monospecific antibodies are reduced.
  • the resulting free cysteines of one of the parental monospecific antibodies form an inter heavy-chain disulfide bond with cysteine residues of a second parental monospecific antibody molecule and simultaneously CH3 domains of the parental antibodies release and reform by dissociationassociation.
  • the CH3 domains of the Fab arms may be engineered to favor heterodimerization over homodimerization.
  • the resulting product is a bispecific antibody having two Fab arms or half molecules which each bind a distinct epitope, i.e., an epitope on EGFR and an epitope on c-Met.
  • the bispecific antibodies of the invention may be generated using the technology described in Int. Pat. Publ. No. WO2011/131746.
  • Mutations F405L in one heavy chain and K409R in the other heavy chain may be used in case of IgGl antibodies.
  • IgG2 antibodies a wild-type IgG2 and a IgG2 antibody with F405L and R409K substitutions may be used.
  • IgG4 antibodies a wild-type IgG4 and a IgG4 antibody with F405L and R409K substitutions may be used.
  • the first monospecific bivalent antibody and the second monospecific bivalent antibody are engineered to have the aforementioned mutation in the Fc region, and the antibodies are incubated together under reducing conditions sufficient to allow the cysteines in the hinge region to undergo disulfide bond isomerization; thereby generating the bispecific antibody by Fab arm exchange.
  • the incubation conditions may optimally be restored to nonreducing.
  • Exemplary reducing agents that may be used are 2- mercaptoethylamine (2-MEA), dithiothreitol (DTT), dithioerythritol (DTE), glutathione, tris(2-carboxyethyl)phosphine (TCEP), L-cysteine and beta- mercaptoethanol.
  • incubation for at least 90 min at a temperature of at least 20°C in the presence of at least 25 mM 2-MEA or in the presence of at least 0.5 mM dithiothreitol at a pH of from 5-8, for example at pH of 7.0 or at pH of 7.4 may be used.
  • Bispecific anti-EGFR/c-Met antibodies used in the methods of the disclosure may also be generated using designs such as the Knob-in-Hole (Genentech), CrossMAbs (Roche) and the electrostatically-matched (Chugai, Amgen, NovoNordisk, Oncomed), the LUZ-Y (Genentech), the Strand Exchange Engineered Domain body (SEEDbody) (EMD Serono), and the Biclonic (Merus).
  • designs such as the Knob-in-Hole (Genentech), CrossMAbs (Roche) and the electrostatically-matched (Chugai, Amgen, NovoNordisk, Oncomed), the LUZ-Y (Genentech), the Strand Exchange Engineered Domain body (SEEDbody) (EMD Serono), and the Biclonic (Merus).
  • Exemplary CH3 substitution pairs forming a knob and a hole are (expressed as modified position in the first CH3 domain of the first heavy chain/ modified position in the second CH3 domain of the second heavy chain): T366Y/F405A, T366W/F405W, F405W/Y407A, T394W/Y407T, T394S/Y407A, T366W/T394S, F405W/T394S and T366W/T366S_L368A_Y407V.
  • CrossMAb technology in addition to utilizing the “knob -in-hole” strategy to promote Fab arm exchange utilizes CH1/CL domain swaps in one half arm to ensure correct light chain pairing of the resulting bispecific antibody (see e.g. , U.S. Patent No. 8,242,247).
  • Other cross-over strategies may be used to generate full length bispecific antibodies of the invention by exchanging variable or constant, or both domains between the heavy chain and the light chain or within the heavy chain in the bispecific antibodies, either in one or both arms. These exchanges include for example VH-CH1 with VL-CL, VH with VL, CH3 with CL and CH3 with CHI as described in Int. Patent Publ. Nos.
  • W02009/080254 W02009/080251, W02009/018386 and W02009/080252.
  • heterodimerization may be promoted by the following substitutions (expressed as modified positions in the first CH3 domain of the first heavy chain/ modified position in the second CH3 domain of the second heavy chain): L351Y F405A Y407V/T394W,
  • SEEDbody technology may be utilized to generate bispecific antibodies of the invention.
  • SEEDbodies have, in their constant domains, select IgG residues substituted with IgA residues to promote heterodimerization as described in U.S. Patent No. US20070287170.
  • Mutations are typically made at the DNA level to a molecule such as the constant domain of the antibody using standard methods.
  • the anti-EGFR/c-Met antibody e.g., bispecific antibody
  • additional therapeutic e.g., chemotherapeutic
  • the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
  • the mode of administration may be any suitable route that delivers the antibody (e.g., bispecific antibody) to the subject in need thereof, such as parenteral administration, e.g., intradermal, intramuscular, intraperitoneal, intravenous or subcutaneous, pulmonary, transmucosal (oral, intranasal, intravaginal, rectal), using a formulation in a tablet, capsule, solution, powder, gel, particle; and contained in a syringe, an implanted device, osmotic pump, cartridge, micropump; or other means appreciated by the skilled artisan, as well known in the art.
  • parenteral administration e.g., intradermal, intramuscular, intraperitoneal, intravenous or subcutaneous, pulmonary, transmucosal (oral, intranasal, intravaginal, rectal)
  • parenteral administration e.g., intradermal, intramuscular, intraperitoneal, intravenous or subcutaneous
  • pulmonary transmucosal
  • Site specific administration may be achieved by, for example intratumoral, intracolic, intraabdominal, intragastric, intracavitary, intrapelvic, intraperitoneal, intrarectal, intrathoracic, intravascular, intralesional, rectal, buccal, sublingual, intranasal, or transdermal delivery.
  • the pharmaceutical composition comprising the anti- EGFR/c-Met antibody is administered via an intravenous infusion.
  • the additional therapeutic (e.g., chemotherapeutic) agent is administered via an intravenous infusion.
  • the pharmaceutical composition comprising the anti- EGFR/c-Met antibody is administered via a subcutaneous injection.
  • the antibody e.g., bispecific antibody
  • the antibody is administered at a dose of about 140 mg to about 1,750 mg, for example, about 700 mg to about 1,400 mg, about 700 mg to about 1,050 mg or about 1,050 mg to about 1,400 mg.
  • the antibody e.g., bispecific antibody
  • the antibody is administered at a dose of about: 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 9
  • the antibody is administered at a dose of about 700 mg, about 1,050 mg or about 1,400 mg. In some embodiments, the antibody is administered at a dose of about 1,050 mg. In certain embodiments, the antibody is administered at a dose of about 1,400 mg. In particular embodiments, the antibody is administered at a dose of about 700 mg.
  • the antibody is administered at a dose of about 350 mg.
  • the antibody is administered at a dose of about 750 mg.
  • the antibody is administered at a dose of about 800 mg.
  • the antibody is administered at a dose of about 850 mg.
  • the antibody is administered at a dose of about 900 mg.
  • the antibody is administered at a dose of about 950 mg.
  • the antibody is administered at a dose of about 1,000 mg.
  • the antibody is administered at a dose of about 1,100 mg.
  • the antibody is administered at a dose of about 1,150 mg.
  • the antibody is administered at a dose of about 1,200 mg.
  • the antibody is administered at a dose of about 1,250 mg.
  • the antibody is administered at a dose of about 1,300 mg.
  • the antibody is administered at a dose of about 1,350 mg.
  • the antibody is administered at a dose of 1,050 mg for body weigh ⁇ 80 kg and 1,400 mg for body weight > 80 kg.
  • the antibody is administered at a dose of 700 mg for body weigh ⁇ 80 kg and 1,050 mg for body weight > 80 kg.
  • the antibody is administered twice a week.
  • the antibody is administered once a week.
  • the antibody is administered once every two weeks. [0169] In certain embodiments, the antibody is administered once every three weeks. [0170] In some embodiments, the antibody is administered once every four weeks. [0171] In certain embodiments, the antibody is administered once a week or once every two weeks. In particular embodiments, the antibody is administered once weekly for the first 4 weeks and then every 2 weeks.
  • the antibody is administered on a 28-day cycle.
  • the subject has a body weight (BW) of ⁇ 80 kg, and the antibody (e.g., bispecific antibody such as amivantamab) is administered at a dose of 700 mg once weekly for the first 4 weeks and then every 2 weeks 28-day cycles.
  • the subject has a body weight of ⁇ 80 kg, and the antibody (e.g., bispecific antibody such as amivantamab) is administered at a dose of 1,050 mg once weekly for the first 4 weeks and then every 2 weeks 28-day cycles.
  • the antibody is administered once weekly for the first 4 weeks and then on Days 1 and 15 (28 days cycle).
  • the subject is administered an IV infusion of amivantamab at a dose of 1,050 or 700 mg if the BW is ⁇ 80 kg, or 1,400 or 1,050 mg if BW is >80 kg, on Days -1, -2, 8, and 22 of Cycle 1 and along with FOLFOX6 chemotherapy (e.g., mFOLFOX6 SoC chemotherapy) on Days 1 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 (each cycle of 28 days).
  • FOLFOX6 chemotherapy e.g., mFOLFOX6 SoC chemotherapy
  • the subject is administered an IV infusion of amivantamab along with FOLFIRI chemotherapy on Days -1, -2, and 8 of Cycle 1 and Days 1 and 15 of Cycle 2.
  • the subject has a body weight (BW) of >80 kg, and the antibody (e.g., bispecific antibody such as amivantamab) is administered at a dose of 1,050 mg once weekly for the first 4 weeks and then every 2 weeks 28-day cycles.
  • the subject has a body weight of >80 kg, and the antibody (e.g., bispecific antibody such as amivantamab) is administered at a dose of 1,400 mg once weekly for the first 4 weeks and then every 2 weeks 28-day cycles.
  • the subject administered an IV infusion of amivantamab at a dose of 1,050 or 700 mg if the BW is ⁇ 80 kg, or 1,400 or 1,050 mg if BW is >80 kg, on Days -1, -2, 8, and 22 of Cycle 1 and along with FOLFOX6 chemotherapy (e.g., mFOLFOX6 SoC chemotherapy) on Days 1 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 (each cycle of 28 days).
  • FOLFOX6 chemotherapy e.g., mFOLFOX6 SoC chemotherapy
  • the subject is administered an IV infusion of amivantamab along with FOLFIRI chemotherapy on days -1, -2, and 8 of Cycle 1 and Days 1 and 15 of Cycle 2.
  • compositions comprising 1,400 mg, 1,050 mg and 700 mg dose of the anti-EGFR/c-Met antibody can be administered in total volumes of about 28 m , 21 m and 14 mb, respectively, with 350 mg/7 mb (50 mg/mb) solution in a single-dose vial.
  • amivantamab-vmjw a prescribing information product insert for RYBREVANT® (amivantamab-vmjw) (www.janssenlabels.com/package-insert/product-monograph/prescribing- information/RYB REVANT-pi.pdf), which is incorporated herein by reference.
  • RYBREVANT® amivantamab-vmjw
  • Additional information regarding the use of amivantamab in patients can be found, for example, in Park K. et al., Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol.
  • the antibody is administered as a monotherapy.
  • the one or more chemotherapeutic agents comprise folinic acid (leucovorin, FOL), fluorouracil (5-FU, F) and oxaliplatin (Eloxatin, OX).
  • FOLFOX e.g., FOLFOX6, for example, mFOLFOX6, a chemotherapy regimen for treatment of colorectal cancer, is known to those skilled in the art. Additional information regarding FOLFOX can be found, for example, in de Gramont et al., J Clin Oncol. 18(16):2938-47 (2000), Toumigand et al., J Clin Oncol. 22(2):229-37 (2004), Goldberg et al., J Clin Oncol.
  • the one or more chemotherapeutic agents comprise folinic acid (leucovorin, FOL), fluorouracil (5-FU, F) and irinotecan (Camptosar, IRI).
  • FOLFIRI folinic acid
  • fluorouracil 5-FU
  • irinotecan Camptosar, IRI.
  • FOLFIRI a chemotherapy regimen for treatment of colorectal cancer, is known to those skilled in the art. Additional information regarding FOLFIRI can be found, for example, in Toumigand et al., J Clin Oncol. 22(2):229-37 (2004), Kamnerdsupaphon et al., J Med Assoc Thai.
  • the method further comprises administering to the subject one or more additional therapeutic agents.
  • the one or more additional therapeutic agents include a T cell expressing chimeric antigen receptor (CAR) (CAR-T cell), a natural killer cell expressing CAR (CAR-NK cell), a macrophage expressing CAR (CAR-M cell), a chemotherapeutic agent, an immune checkpoint inhibitor, a T-cell redirector, radiation therapy, surgery and a standard of care drug.
  • the one or more additional therapeutic agents comprises chemotherapy, radiation therapy, surgery, a targeted anti -cancer therapy, a kinase inhibitor, or a combination thereof.
  • the one or more additional therapeutic agents are one or more anti-cancer therapies. In some embodiments, the one or more additional therapeutic agents comprise one or more chemotherapeutic agents.
  • a non-exhaustive list of chemotherapeutic agents considered for use in combination therapies include anastrozole (Arimidex®), bicalutamide (Casodex®), bleomycin sulfate (Blenoxane®), busulfan (Myleran®), leucovorin calcium, melphalan (Alkeran®), 6- mercaptopurine (Purinethol®), methotrexate (Folex®), mitoxantrone (Novantrone®), mylotarg, paclitaxel (Taxol®), phoenix (Y ttrium90/MX-DTPA), pentostatin, polifeprosan 20 with carmustine implant (Gliadel®), dactinomycin (Actinomycin D, Cosmegan), daunorubicin hydrochloride (Cerubidine®), daunorubicin citrate liposome injection (DaunoXome®), dexamethasone,
  • Example alkylating agents include, without limitation, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazenes): uracil mustard (Aminouracil Mustard®, Chlorethaminacil®, Haemanthamine®, Nordopan®, Uracil Nitrogen Mustard®, Uracillost®, Uracilmostaza®, Uramustin®, Uramustine®), chlormethine (Mustargen®), cyclophosphamide (Cytoxan®, Neosar®, Clafen®, Endoxan®, Procytox®, RevimmuneTM), ifosfamide (Mitoxana®), melphalan (Alkeran®), Chlorambucil (Leukeran®), pipobroman (Amedel®, Vercyte®), triethylenemelamine (Hemel®, Hexylen®, Hexastat®), De
  • alkylating agents include, without limitation, Oxaliplatin (Eloxatin®); Melphalan (also known as L-PAM, L-sarcolysin, and phenylalanine mustard, Alkeran®); Altretamine (also known as hexamethylmelamine (HMM), Hexylen®); Carmustine (BiCNU®);
  • Bendamustine (Treanda®); Busulfan (Busulfex® and Myleran®); Carboplatin (Paraplatin®); Temozolomide (Temodar® and Temodal®); Dactinomycin (also known as actinomycin-D, Cosmegen®); Lomustine (also known as CCNU, CeeNU®); Cisplatin (also known as CDDP, Platinol® and Platinol®-AQ); Chlorambucil (Leukeran®); Cyclophosphamide (Cytoxan® and Neosar®); dacarbazine (also known as DTIC, DIC and imidazole carboxamide, DTIC- Dome®); Altretamine (also known as hexamethylmelamine (HMM), Hexylen®); Ifosfamide (Ifex®); Prednumustine; Procarbazine (Matulane®); Mechlorethamine (also known as nitrogen mustard, mustine and mech
  • the one or more additional therapeutic agents comprise a kinase inhibitor.
  • the kinase inhibitor comprises an inhibitor of EGFR, an inhibitor of c-Met, an inhibitor of HER2, an inhibitor of HER3, an inhibitor of HER4, an inhibitor of VEGFR, an inhibitor of AXL or a combination thereof.
  • the kinase inhibitor is an inhibitor of EGFR.
  • the kinase inhibitor is an inhibitor of c-Met.
  • the kinase inhibitor is an inhibitor of HER2.
  • the kinase inhibitor is an inhibitor of HER3.
  • the kinase inhibitor is an inhibitor of HER4.
  • the kinase inhibitor is an inhibitor of VEGFR. In certain embodiments, the kinase inhibitor is an inhibitor of or AXL. [0186] In some embodiments, the kinase inhibitor comprises erlotinib, gefitinib, lapatinib, vandetanib, afatinib, osimertinib, lazertinib, poziotinib, criotinib, cabozantinib, capmatinib, axitinib, lenvatinib, nintedanib, regorafenib, pazopanib, sorafenib, sunitinib or a combination thereof.
  • the kinase inhibitor is erlotinib. In particular embodiments, the kinase inhibitor is gefitinib. In some embodiments, the kinase inhibitor is lapatinib. In certain embodiments, the kinase inhibitor is vandetanib. In some embodiments, the kinase inhibitor is afatinib. In some embodiments, the kinase inhibitor is osimertinib. In certain embodiments, the kinase inhibitor is lazertinib. In particular embodiments, the kinase inhibitor is poziotinib. In some embodiments, the kinase inhibitor is criotinib.
  • the kinase inhibitor is cabozantinib. In some embodiments, the kinase inhibitor is capmatinib. In some embodiments, the kinase inhibitor is axitinib. In certain embodiments, the kinase inhibitor is lenvatinib. In some embodiments, the kinase inhibitor is nintedanib. In particular embodiments, the kinase inhibitor is regorafenib. In certain embodiments, the kinase inhibitor is pazopanib. In some embodiments, the kinase inhibitor is sorafenib. In particular embodiments, the kinase inhibitor is sunitinib.
  • the one or more prior anti-cancer therapies comprises carboplatin, paclitaxel, gemcitabine, cisplatin, vinorelbine, docetaxel, palbociclib, crizotinib, PD-(L) 1 axis inhibitor, an inhibitor of EGFR, an inhibitor of c-Met, an inhibitor of HER2, an inhibitor of HER3, an inhibitor of HER4, an inhibitor of VEGFR, an inhibitor of AXL, erlotinib, gefitinib, lapatinib, vandetanib, afatinib, osimertinib, lazertinib, poziotinib, criotinib, cabozantinib, capmatinib, axitinib, lenvatinib, nintedanib, regorafenib, pazopanib, sorafenib or sunitinib, or any
  • Anti-cancer therapies that may be administered in combination with the anti- EGFR/c-Met antibody (e.g., bispecific antibody) in the methods of the disclosure include any one or more of the chemotherapeutic drugs or other anti -cancer therapeutics known to those of skill in the art.
  • Chemotherapeutic agents are chemical compounds useful in the treatment of cancer and include growth inhibitory agents or other cytotoxic agents and include alkylating agents, anti-metabolites, anti-microtubule inhibitors, topoisomerase inhibitors, receptor tyrosine kinase inhibitors, angiogenesis inhibitors and the like.
  • chemotherapeutic agents include alkylating agents such as thiotepa and cyclosphosphamide (CYTOXAN®); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphaoramide and trimethylolomelamine; nitrogen mustards such as chlorambucil, chlomaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine,
  • anti-hormonal agents that act to regulate or inhibit hormone action on tumors
  • anti-estrogens including for example tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LY 117018, onapristone, and toremifene (FARESTON®); and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; and pharmaceutically acceptable salts, acids or derivatives of any of the above.
  • the anti-EGFR/c-Met antibody e.g, bispecific antibody
  • the one or more additional therapeutic agents e.g., chemotherapeutic agents
  • the antibody and the one or more additional therapeutic agents are administered separately (e.g., sequentially).
  • the one or more anti-cancer agents may be administered using recommended doses and dosages of the anti -cancer agent.
  • patient can be used interchangeably herein.
  • Patient in need thereof or “subject in need thereof’ refers to a mammalian subject, preferably human, diagnosed with or suspected of having a disease, to whom will be or has been administered a bi-specific anti-EGFR anti-MET antibody according to a method of the invention.
  • Patient in need thereof or “subject in need thereof’ includes those subjects already with the undesired physiological change or disease well as those subjects prone to have the physiological change or disease.
  • the subject is 18 years of age or older, e.g., 18 to less than 40 years of age, 18 to less than 45 years of age, 18 to less than 50 years of age, 18 to less than
  • the subject is a child.
  • the subject is 18 years of age or younger, e.g., 0-18 years of age, 0-12 years of age, 0-16 years of age, 0-17 years of age, 2-12 years of age, 2-16 years of age, 2-17 years of age, 2-18 years of age, 3-12 years of age, 3-16 years of age, 3-17 years of age, 3-18 years of age, 4-12 years of age, 4-16 years of age, 4-17 years of age, 4-18 years of age, 6-12 years of age, 6-16 years of age, 6-17 years of age, 6-18 years of age, 9-12 years of age, 9-16 years of age, 9-17 years of age, 9-18 years of age, 12-16 years of age, 12-17 years of age or 12-18 years of age.
  • the subject has been diagnosed with CRC (e.g., mCRC) for at least about 1 month, e.g., at least about: 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 18 months, 2 years, 30 months, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years or 10 years.
  • CRC e.g., mCRC
  • the subject is newly diagnosed with CRC (e.g., mCRC).
  • the CRC is adenocarcinoma.
  • the subject is treatment naive.
  • the subject has received one or more prior anti-cancer therapies.
  • the one or more prior anti-cancer therapies comprises one or more chemotherapeutic agents, checkpoint inhibitors, targeted anti-cancer therapies or kinase inhibitors, or any combination thereof.
  • the subject is relapsed or resistant to treatment with one or more prior anti -cancer therapies.
  • the subject is resistant or has acquired resistance to an EGFR inhibitor.
  • EGFR inhibitors for which cancer may acquire resistance are anti-EGFR antibodies cetuximab (ERBITUX®), pantinumumab (VECTIBIX®), matuzumab, nimotuzumab, small molecule EGFR inhibitors erlotinib (TARCEVA® ), gefitinib (IRESSA®), EKB-569 (pelitinib, irreversible EGFR TKI), pan-ErbB and other receptor tyrosine kinase inhibitors, lapatinib (EGFR and HER2 inhibitor), pelitinib (EGFR and HER2 inhibitor), vandetanib (ZD6474, ZACTIMATM, EGFR, VEGFR2 and RET TKI), PF00299804 (dacomitinib, irreversible pan-ErbB TKI) , CI- 1033 (irreversible pan
  • Various qualitative and/or quantitative methods may be used to determine if a subject is resistant, has developed or is susceptible to developing a resistance to treatment with an anti -cancer therapy.
  • Symptoms that may be associated with resistance to an anticancer therapy include a decline or plateau of the well-being of the patient, an increase in the size of a tumor, arrested or slowed decline in growth of a tumor, and/or the spread of cancerous cells in the body from one location to other organs, tissues or cells.
  • Reestablishment or worsening of various symptoms associated with cancer may also be an indication that a subject has developed or is susceptible to developing resistance to an anticancer therapy, such as anorexia, cognitive dysfunction, depression, dyspnea, fatigue, hormonal disturbances, neutropenia, pain, peripheral neuropathy, and sexual dysfunction.
  • the symptoms associated with cancer may vary according to the type of cancer.
  • symptoms associated with cervical cancer may include abnormal bleeding, unusual heavy vaginal discharge, pelvic pain that is not related to the normal menstrual cycle, bladder pain or pain during urination, and bleeding between regular menstrual periods, after sexual intercourse, douching, or pelvic exam.
  • Symptoms associated with lung cancer may include persistent cough, coughing up blood, shortness of breath, wheezing chest pain, loss of appetite, losing weight without trying and fatigue.
  • Symptoms for liver cancer may include loss of appetite and weight, abdominal pain, especially in the upper right part of abdomen that may extend into the back and shoulder, nausea and vomiting, general weakness and fatigue, an enlarged liver, abdominal swelling (ascites), and a yellow discoloration of the skin and the whites of eyes (jaundice).
  • One skilled in oncology may readily identify symptoms associated with a particular cancer type.
  • Exemplary PD-(L)1 axis inhibitors are antibodies that bind PD-1 such as nivolumab (OPDIVO®), pembrolimumab (KEYTRUDA®), sintilimab, cemiplimab (LIBTAY O®), tripolibamab, tislelizumab, spartalizumab, camrelizumab, dostralimab, genolimzumab or cetrelimab, or antibodies that bind PD-L1, such as PD-L1 antibodies are envafolimab, atezolizumab (TECENTRIQ®), durvalumab (IMFINZI®) and avelumab (BAVENCIO®).
  • OPDIVO® nivolumab
  • KEYTRUDA® pembrolimumab
  • sintilimab sintilimab
  • cemiplimab LIBTAY O®
  • Marketed antibodies may be purchased via authorized distributor or pharmacy.
  • the amino acid sequences structures of the small molecules can be found from USAN and/or INN submissions by the companies of from CAS registry.
  • the subject has EGFR or c-Met expressing cancer.
  • Exemplary c-Met activating mutations include point mutations, deletion mutations, insertion mutations, inversions or gene amplifications that lead to an increase in at least one biological activity of a c-Met protein, such as elevated tyrosine kinase activity, formation of receptor homodimers and heterodimers, enhanced ligand binding etc. Mutations can be located in any portion of the c-Met gene or regulatory regions associated with the gene, such as mutations in the kinase domain of c-Met. Exemplary c-Met activating mutations are mutations at residue positions N375, V13, V923, R175, V136, L229, S323, R988, S1058/T1010 and E168. Methods for detecting EGFR and c-Met mutations or gene amplifications are well known.
  • the subject has been characterized with wild-type KRAS, NRAS and BRAF. In some embodiments, the subject has been characterized with wild-type EGFR. Diagnosis
  • Certain embodiments of the present disclosure concern determining the presence of mutations in a KRAS, NRAS, BRAF, or EGFR gene.
  • Mutation detection methods are known the art, including PCR followed by nucleic acid sequencing, FISH, CGH, or next generation sequencing (NGS).
  • the mutations are detected by DNA sequencing, such as next generation sequencing (NGS), by using a tumor tissue sample or circulating free DNA from plasma.
  • the method comprises: a) providing a biological sample from the subject; b) determining presence or absence of amutation in KRAS, NRAS, BRAF, or EGFR gene in the sample; c) administering or providing for administration the anti-EGFR/c-Met antibody to the subject determined to have wild type KRAS, NRAS, BRAF, or EGFR gene.
  • the biological sample is a blood sample.
  • the biological sample is a tumor tissue biopsy.
  • the disclosure provides a method of treating mCRC in a subject having wild type KRAS, NRAS, BRAF, or EGFR gene, comprising administering a therapeutically effective amount of an isolated bispecific anti-EGFR/c-Met antibody to the subject, wherein the bispecific anti-EGFR/c-Met antibody comprises a first domain that specifically binds EGFR and a second domain that specifically binds c-Met, wherein the first domain comprises a HCDR1 of SEQ ID NO: 1, a HCDR2 of SEQ ID NO: 2, a HCDR3 of SEQ ID NO: 3, a LCDR1 of SEQ ID NO: 4, a LCDR2 of SEQ ID NO: 5 and a LCDR3 of SEQ ID NO: 6; and the second domain comprises the HCDR1 of SEQ ID NO: 7, the HCDR2 of SEQ ID NO: 8, the HCDR3 of SEQ ID NO: 9, the LCDR1 of SEQ ID NO: 10, the LCDR2 of S
  • the disclosure provides a method of treating mCRC in a subject having wild type KRAS, NRAS, BRAF, or EGFR gene, comprising administering a therapeutically effective amount of an isolated bispecific anti-EGFR/c-Met antibody to the subject, wherein the bispecific anti-EGFR/c-Met antibody comprises a first domain that specifically binds EGFR and a second domain that specifically binds c-Met, wherein the first domain comprises a VH of SEQ ID NO: 13 and a VL of SEQ ID NO: 14; and the second domain comprises the VH of SEQ ID NO: 15 and the VL of SEQ ID NO: 16.
  • the disclosure provides a method of treating mCRC in a subject having wild type KRAS, NRAS, BRAF, or EGFR gene, comprising administering a therapeutically effective amount of an isolated bispecific anti-EGFR/c-Met antibody to the subject, wherein the bispecific anti-EGFR/c-Met antibody comprises a HC1 of SEQ ID NO: 17, a LCl of SEQ ID NO: 18, a HC2 of SEQ ID NO: 19 and a LC2 of SEQ ID NO: 20.
  • the disclosure provides a method of treating mCRC in a subject having wild type KRAS, NRAS, BRAF, or EGFR gene, comprising administering a therapeutically effective amount of an isolated bispecific anti-EGFR/c-Met antibody to the subject, wherein the bispecific anti-EGFR/c-Met antibody is amivantamab.
  • a method of treating colorectal cancer in a subject in need thereof comprising administering a therapeutically effective amount of an anti-epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody to the subject.
  • EGFR anti-epidermal growth factor receptor
  • c-Met hepatocyte growth factor receptor
  • the antibody comprises: a) a first domain that specifically binds EGFR, comprising heavy chain complementarity determining region 1 (HCDR1), HCDR2, HCDR3, light chain complementarity determining region 1 (LCDR1), LCDR2 and LCDR3 amino acid sequences of SEQ ID NOs: l, 2, 3, 4, 5 and 6, respectively; and b) a second domain that specifically binds c-Met, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 amino acid sequences of SEQ ID NOs:7, 8, 9, 10, 11 and 12, respectively.
  • the antibody comprises a first heavy chain (HC1) of SEQ ID NO: 17, a first light chain (LC1) of SEQ ID NO: 18, a second heavy chain (HC2) of SEQ ID NO: 19 and a second light chain (LC2) of SEQ ID NO:20.
  • HC1 first heavy chain
  • LC1 first light chain
  • HC2 second heavy chain
  • LC2 second light chain
  • LC2 second light chain
  • the antibody is an isolated bispecific antibody.
  • the bispecific antibody is amivantamab.
  • the antibody comprises a biantennary glycan structure with a fucose content of about 1% to about 15%.
  • any one of embodiments 1-8 wherein the antibody is administered at a dose of about 700 mg to about 1,400 mg.
  • the method of embodiment 10, wherein the antibody is administered at a dose of about 700 mg.
  • the method of any one of embodiments 1-13 wherein the antibody is administered once a week or once every two weeks.
  • any one of embodiments 1-15 wherein the antibody is administered on a 28 -day cycle.
  • the method of any one of embodiments 1-16 wherein the antibody is administered as a monotherapy.
  • the one or more chemotherapeutic agents comprise FOLFOX, wherein FOLFOX comprises folinic acid, fluorouracil and oxaliplatin.
  • chemotherapeutic agents comprise FOLFIRI, wherein FOLFIRI comprises folinic acid, fluorouracil and irinotecan.
  • Example 1 Amivantamab in Patients with Advanced or Metastatic Colorectal Cancer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/IB2022/061991 2021-12-09 2022-12-09 Use of amivantamab to treat colorectal cancer Ceased WO2023105479A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2022407875A AU2022407875A1 (en) 2021-12-09 2022-12-09 Use of amivantamab to treat colorectal cancer
MX2024007066A MX2024007066A (es) 2021-12-09 2022-12-09 Uso de amivantamab para tratar el cancer colorrectal.
EP22826446.1A EP4444426A1 (en) 2021-12-09 2022-12-09 Use of amivantamab to treat colorectal cancer
KR1020247022472A KR20240112963A (ko) 2021-12-09 2022-12-09 대장암을 치료하기 위한 아미반타맙의 용도
JP2024534144A JP2025500784A (ja) 2021-12-09 2022-12-09 結腸直腸癌を治療するためのアミバンタマブの使用
CN202280081380.9A CN118414167A (zh) 2021-12-09 2022-12-09 埃万妥单抗用于治疗结肠直肠癌的用途
IL313410A IL313410A (en) 2021-12-09 2022-12-09 Use of amivantamab to treat colorectal cancer
CA3241933A CA3241933A1 (en) 2021-12-09 2022-12-09 Use of amivantamab to treat colorectal cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163287557P 2021-12-09 2021-12-09
US63/287,557 2021-12-09
US202163290765P 2021-12-17 2021-12-17
US63/290,765 2021-12-17

Publications (1)

Publication Number Publication Date
WO2023105479A1 true WO2023105479A1 (en) 2023-06-15

Family

ID=84537874

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2022/061991 Ceased WO2023105479A1 (en) 2021-12-09 2022-12-09 Use of amivantamab to treat colorectal cancer

Country Status (9)

Country Link
US (2) US20230183360A1 (https=)
EP (1) EP4444426A1 (https=)
JP (1) JP2025500784A (https=)
KR (1) KR20240112963A (https=)
AU (1) AU2022407875A1 (https=)
CA (1) CA3241933A1 (https=)
IL (1) IL313410A (https=)
MX (1) MX2024007066A (https=)
WO (1) WO2023105479A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202547867A (zh) * 2024-01-16 2025-12-16 美商健生生物科技公司 使用阿米維單抗治療結腸直腸癌
WO2026022733A1 (en) * 2024-07-23 2026-01-29 Janssen Biotech, Inc. Combination therapies for the treatment of colorectal cancer
WO2026022739A1 (en) * 2024-07-23 2026-01-29 Janssen Biotech, Inc. Combination therapies for the treatment of colorectal cancer

Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
WO1992001047A1 (en) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
WO1998044001A1 (en) 1997-03-27 1998-10-08 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
US20070287170A1 (en) 2006-03-24 2007-12-13 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2009018386A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
WO2009080252A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Bivalent, bispecific antibodies
WO2009080251A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Bivalent, bispecific antibodies
WO2009080254A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Bivalent, bispecific antibodies
WO2009085462A1 (en) 2007-12-19 2009-07-09 Centocor, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
US20100015133A1 (en) 2005-03-31 2010-01-21 Chugai Seiyaku Kabushiki Kaisha Methods for Producing Polypeptides by Regulating Polypeptide Association
US20100028637A1 (en) 2005-06-22 2010-02-04 Sunjuet Deutschland Gmbh Multi-Layer Film Comprising a Barrier Layer and an Antistatic Layer
US20110123532A1 (en) 2009-04-27 2011-05-26 Oncomed Pharmaceuticals, Inc. Method for Making Heteromultimeric Molecules
WO2011131746A2 (en) 2010-04-20 2011-10-27 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
US20120149876A1 (en) 2010-11-05 2012-06-14 Zymeworks Inc. Stable Heterodimeric Antibody Design with Mutations in the Fc Domain
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20130195849A1 (en) 2011-11-04 2013-08-01 Zymeworks Inc. Stable Heterodimeric Antibody Design with Mutations in the Fc Domain
WO2014081954A1 (en) * 2012-11-21 2014-05-30 Janssen Biotech, Inc. BISPECIFIC EGFR/c-Met ANTIBODIES
WO2020174370A2 (en) * 2019-02-26 2020-09-03 Janssen Biotech, Inc. Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
WO2021161262A1 (en) * 2020-02-12 2021-08-19 Janssen Biotech, Inc. TREATMENT OF PATIENTS HAVING c-MET EXON 14 SKIPPING MUTATIONS

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
WO1992001047A1 (en) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
WO1998044001A1 (en) 1997-03-27 1998-10-08 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
US20100015133A1 (en) 2005-03-31 2010-01-21 Chugai Seiyaku Kabushiki Kaisha Methods for Producing Polypeptides by Regulating Polypeptide Association
US20100028637A1 (en) 2005-06-22 2010-02-04 Sunjuet Deutschland Gmbh Multi-Layer Film Comprising a Barrier Layer and an Antistatic Layer
US20070287170A1 (en) 2006-03-24 2007-12-13 Merck Patent Gmbh Engineered heterodimeric protein domains
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
WO2009018386A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
WO2009085462A1 (en) 2007-12-19 2009-07-09 Centocor, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
WO2009080254A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Bivalent, bispecific antibodies
WO2009080251A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Bivalent, bispecific antibodies
WO2009080252A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20110123532A1 (en) 2009-04-27 2011-05-26 Oncomed Pharmaceuticals, Inc. Method for Making Heteromultimeric Molecules
WO2011131746A2 (en) 2010-04-20 2011-10-27 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
US20120149876A1 (en) 2010-11-05 2012-06-14 Zymeworks Inc. Stable Heterodimeric Antibody Design with Mutations in the Fc Domain
US20130195849A1 (en) 2011-11-04 2013-08-01 Zymeworks Inc. Stable Heterodimeric Antibody Design with Mutations in the Fc Domain
WO2014081954A1 (en) * 2012-11-21 2014-05-30 Janssen Biotech, Inc. BISPECIFIC EGFR/c-Met ANTIBODIES
US9593164B2 (en) 2012-11-21 2017-03-14 Janssen Biotech, Inc. Bispecific EGFR/c-Met antibodies
WO2020174370A2 (en) * 2019-02-26 2020-09-03 Janssen Biotech, Inc. Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
WO2021161262A1 (en) * 2020-02-12 2021-08-19 Janssen Biotech, Inc. TREATMENT OF PATIENTS HAVING c-MET EXON 14 SKIPPING MUTATIONS

Non-Patent Citations (34)

* Cited by examiner, † Cited by third party
Title
"GenBank", Database accession no. NP_005219
BILLERSCHRAG, JAMA, vol. 325, no. 7, 2021, pages 669 - 85
CHEN ET AL., MEDICINE (BALTIMORE, vol. 95, no. 46, 2016, pages e5221
CHO BC ET AL.: "MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small cell lung cancer", FUTURE ONCOL, 16 December 2021 (2021-12-16)
CHOTHIA ET AL., J MOL BIOL, vol. 196, 1987, pages 901 - 17
FERRARA ET AL., BIOTECHNOL BIOENG, vol. 93, 2006, pages 851 - 861
FERRARA ET AL., J BIOL CHEM, vol. 281, 2006, pages 5032 - 5036
GOLDBERG ET AL., J CLIN ONCOL, vol. 22, no. 1, 2004, pages 23 - 30
GRAMONT ET AL., J CLIN ONCOL., vol. 18, no. 16, 2000, pages 2938 - 47
HONEGGERPLUCKTHUN, J MOL BIOL, vol. 309, 2001, pages 657 - 70
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, PUBLIC HEALTH SERVICE
KAMNERDSUPAPHON ET AL., J MED ASSOC THAI, vol. 90, no. 10, 2007, pages 2121 - 7
KIRSTEIN ET AL., ONCOLOGIST, vol. 19, no. 11, 2014, pages 1156 - 68
KNAPPIK ET AL., J. MOL. BIOL., vol. 296, 2000, pages 57 - 86
KONNO ET AL., CYTOTECHNOLOGY, vol. 64, 2012, pages 249 - 65
LEFRANC ET AL., DEV COMP IMMUNOL, vol. 27, 2003, pages 55 - 77
MARTINTHORNTON, JBMOL BIOL, vol. 263, 1996, pages 800 - 15
MORI ET AL., BIOTECHNOL BIOENG, vol. 88, 2004, pages 901 - 908
NEUGUT ET AL., CLIN COLORECTAL CANCER, vol. 18, no. 2, 2019, pages 133 - 40
OLIVIER ET AL., MABS, vol. 2, no. 4, 2010
PARK K. ET AL.: "Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study", J CLIN ONCOL, vol. 39, no. 30, 20 October 2021 (2021-10-20), pages 3391 - 3402
SAWICKI ET AL., CANCERS (BASEL, vol. 13, no. 9, 2021, pages 2025
SHI ET AL., J. MOL. BIOL., vol. 397, 2010, pages 385 - 96
SHIELDS ET AL., J BIOL CHEM, vol. 277, 2002, pages 26733 - 26740
SHINKAWA ET AL., J BIOL CHEM, vol. 278, 2003, pages 3466 - 3473
SOBRERO ET AL., JOURNAL OF CLINICAL ONCOLOGY, vol. 36, no. 15, 2018, pages 1478 - 85
TOURNIGAND ET AL., J CLIN ONCOL., vol. 22, no. 2, 2004, pages 229 - 37
TSAI ET AL., SPRINGERPLUS, vol. 5, no. 1, 2016, pages 1318
ULLRICH ET AL., NATURE, vol. 309, 1984, pages 418 - 425
VYSE SHUANG PH: "Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer", EXPERT REV ANTICANCER THER., 16 December 2021 (2021-12-16)
WIEMANN ET AL.: "Medical Oncology", 1985, MCMILLAN
WU ET AL., J EXP MED, vol. 132, 1970, pages 211 - 50
YUN JIYEON ET AL: "Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC", CANCER DISCOVERY, vol. 10, no. 8, 15 May 2020 (2020-05-15), US, pages 1194 - 1209, XP093004088, ISSN: 2159-8274, Retrieved from the Internet <URL:https://watermark.silverchair.com/1194.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAtUwggLRBgkqhkiG9w0BBwagggLCMIICvgIBADCCArcGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMGjonfT99v64HTn-VAgEQgIICiPF5L7iBhCX9gmg0hpgoJgOJ5uT0OkvD8B4jlB2TBdILpvFS9QF5_MmuGrKybXEmCrt0_HW8e4eFpmBbmCStFxtyq2ka-ro> DOI: 10.1158/2159-8290.CD-20-0116 *
ZHOU ET AL., BIOTECHNOL BIOENG, vol. 99, 2008, pages 652 - 65

Also Published As

Publication number Publication date
US20250257139A1 (en) 2025-08-14
AU2022407875A1 (en) 2024-07-25
KR20240112963A (ko) 2024-07-19
IL313410A (en) 2024-08-01
CA3241933A1 (en) 2023-06-15
EP4444426A1 (en) 2024-10-16
MX2024007066A (es) 2024-06-21
US20230183360A1 (en) 2023-06-15
JP2025500784A (ja) 2025-01-15

Similar Documents

Publication Publication Date Title
US20250257139A1 (en) Use of Amivantamab to Treat Colorectal Cancer
US12528869B2 (en) Treatment of non-small cell lung cancer with EGFR mutations
WO2024241273A1 (en) Methods for treatment of non-small cell lung cancer (nsclc)
WO2023148702A1 (en) Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
US20220372581A1 (en) Methods for Identifying Cancer Patients for Combination Treatment
EP4716701A1 (en) Use of amivantamab to treat colorectal cancer
US20260048065A1 (en) Methods for treatment of non-small cell lung cancer (nsclc)
WO2026038160A1 (en) Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
CA3222287A1 (en) First line treatment in egfr exon 20 insertion-mutated advanced non-small cell lung cancer
EP4680639A1 (en) Combination therapies with bi-specific anti-egfr/c-met antibodies and anti-pd-1 antibodies
HK40116078A (zh) 用於减少使用egfr/met双特异性抗体治疗的患者的输注相关反应的方法
CN118414167A (zh) 埃万妥单抗用于治疗结肠直肠癌的用途
CN118679186A (zh) 用于减少使用egfr/met双特异性抗体治疗的患者的输注相关反应的方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22826446

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12024551333

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: P2024-01428

Country of ref document: AE

WWE Wipo information: entry into national phase

Ref document number: 313410

Country of ref document: IL

Ref document number: 3241933

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2024534144

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202280081380.9

Country of ref document: CN

Ref document number: MX/A/2024/007066

Country of ref document: MX

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112024011083

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 11202403536Q

Country of ref document: SG

WWE Wipo information: entry into national phase

Ref document number: 202491464

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20247022472

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2022826446

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022826446

Country of ref document: EP

Effective date: 20240709

ENP Entry into the national phase

Ref document number: 2022407875

Country of ref document: AU

Date of ref document: 20221209

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112024011083

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20240603